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ABSTRACT

The dystroglycan protein is one of many that attach skeletal muscle fibers to the
basement membrane at the myotendinous junction. In the alpha-subunit of the dystroglycan
molecule, there are sugar chains that help with the adhesion of the molecule to the basement
membrane. A mutation in any gene that codes for an enzyme that adds these sugar chains
can result in a form of congenital muscle disease called secondary dystroglycanopathy.
One of the genes that codes for an enzyme that adds sugar chains is GMPPB and a mutation
in this gene results in GMPPB-associated dystroglycanopathy. Using zebrafish as a model
for studying dystroglycanopathies has become popular due to their high fecundity, low cost
of maintenance, and transparency during early developmental stages. We confirmed
through in situ hybridization that matrix metalloproteinase-13 (mmp13a) is upregulated in
gmppb mutants and is thought to be a contributor to the progression of the disease. We
used a mutant gmppb line of zebrafish to see if chemical inhibition of Mmp13 in the
embryos would rescue the mutant phenotypes. We also used a morpholino knockdown
strategy when the phenotypes of the gmppb mutants became too variable. We found that
chemical inhibition of Mmp13 did not rescue either the gmppb mutant or morphant
phenotype. Based off of our results from these experiments, we can conclude that chemical
inhibition of Mmp13 does not appear to be a viable treatment for patients diagnosed with
GMPPB-associated dystroglycanopathy. We also checked to see if there was colocalization of Mmp13 with macrophages using a fluorescent macrophage reporter
transgenic zebrafish line and antibody staining for Mmp13 protein. After staining and
imaging the embryos via confocal microscopy, we did not see any co-localization of

Mmp13 with macrophages. From the results of this experiment, we can conclude that
macrophages are likely not the source of Mmp13.
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INTRODUCTION

1. Skeletal muscle: Major Functions and the Form that Enables Those Functions
Skeletal muscle is one of the three main types of muscle (the other two being
cardiac and smooth muscle). It is what controls the voluntary movements of the body
such as walking, running, talking, etc. The muscles you use to perform these actions work
through contraction of smaller muscle fibers in unison. These fibers are made up of actin
and myosin filaments which slide past each other, contracting the filaments. Hundreds of
filaments are arranged together which makes up the individual muscle fiber. When the
filaments contract, the muscle fiber contracts. The fibers are packed into a muscle bundle,
which then contracts, followed by the groups of muscle bundles (the muscle itself)
contracting. Together, all of these fibers and bundles pull on the skeletal system to move
the body and perform the action needed.
Along with moving the skeletal system, skeletal muscle performs a variety of
other functions. Skeletal muscle uses ATP as the energetic molecule for the muscle fibers
to contract and the muscle to apply the force it needs. During frequent use, such as
intense exercise, the breakage of ATP produces heat. This production of heat travels to
the bloodstream where blood temperatures also rise (González-Alonso, Quistorff,
Krustrup, Bangsbo, & Saltin, 2000). These contractions are controlled by motor neurons
which send signals to the muscle fibers to contract. Motor neurons can be stimulated by a
variety of signals. Hormones are heavily involved in the signaling of motor neurons,
specifically thyroid hormone (TH). TH can be split up into two major hormones,
triiodothyronine (T3) and thyroxine (T4). T4 increases motor neuron stimulation by
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rapidly signaling for the activity of Na/K-ATPase, also more commonly known as the
sodium-potassium pump, to increase in the skeletal myotubes (Bloise, Cordeiro, &
Ortiga-Carvalho, 2018). This increased activity of the sodium-potassium pump, in
consequence, increases the transmembrane resting potential of the motor neurons, which
leads to an increase in the frequency of spontaneously occurring action potentials (Bloise
et al., 2018). An example of spontaneously occurring action potentials in the skeletal
muscle is shivering. Shivering is the rapid contraction of the skeletal muscle in the body
to produce heat when the homeostasis of the body dips below optimal temperatures. This
is an extremely advantageous adaptation to cold in response to the human body being
devoid of fur. It is our last line of defense against hypothermia and an important function
of our skeletal muscle.
While the thyroid is an important endocrine organ that has many interactions with
the skeletal muscle, recent studies have found that skeletal muscle itself may be partly an
endocrine organ. This was proposed after the discovery of secreted molecules called
myokines. Myokines are molecules that are secreted by the muscle fibers that have
autocrine, paracrine, and exocrine function (Huh, 2018). These molecules are important
to the health and function of the muscle fibers. The autocrine and paracrine effects of
myokines include the regulation of muscle growth and lipid metabolism, which can help
provide a feedback loop for muscle adaptation to exercise training; while the endocrine
function mediates the whole body effects of exercise (Huh, 2018). The endocrine
function of these myokines also affects the liver, adipose tissue, and bone (Ost, Coleman,
Kasch, & Klaus, 2016) (See Figure 1). This linkage to other major organs of the body
shows the importance of the skeletal muscle and how this organ is tied to so many other
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organs. Further exploration into skeletal muscle and diseases that affect it is of utmost
importance as the symptoms may extend into many other regions of the body.

Figure 1, taken from Ost et al., 2016: Stress on the skeletal muscle can induce cell
signaling through the use of myokines. The myokines produced as a result of cellular
stress are highlighted in red, exercise induced myokines are highlighted in blue, and
myokines produced by both conditions are highlighted in gray.

While keeping the body at homeostasis is an important characteristic of skeletal
muscle, the main function of skeletal muscle is to produce the force necessary to move
the body. The individual muscle fibers are the star players of the contraction. The fibers
are stretched and placed under immense tension which helps increase the force of
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contraction. In order for the muscle to pull on the skeletal system, the fibers need to be
kept under this tension. In order for this to happen, there must be proper connection of the
fibers to their extracellular matrix (ECM). Improper connection of the fibers can cause a
variety of symptoms that can lead to great difficulty in doing simple motor movements in
someone who has muscle fiber attachment problems. When someone has these muscle
problems, they may not be able to use some or all of their muscles, such as the biceps in
the arms or quadricep in the leg, normally. When this happens, the muscle fibers become
weak and shrink in size, with an increase in fiber mortality. This fiber death can be due to
anoikis – cell death when adhesion to ECM is lost. The shrinking of muscle is called
muscle atrophy and is a common symptom of many muscle diseases. The process of
muscle atrophy can be brought on by a variety of stressors that include neural inactivity,
mechanical unloading, inflammation, metabolic stress, and elevated glucocorticoids
(Bodine & Baehr, 2014). All of these stressors contribute to symptoms of muscle
diseases.
A common method to combat muscle atrophy is to try and use exercise to build
and strengthen the muscle. Building of the muscle is called muscle hypertrophy and it has
been shown to slow the progression of atrophy in muscle disease (Kley, Tarnopolsky, &
Vorgerd, 2013). People who go to the gym to strengthen their skeletal muscle do so
through this process. When you go through intense exercise, you put a lot of strain on the
muscle fibers, which can break them. This is the feeling of being “sore” after a workout.
Your body recruits amino acids to help rebuild these fibers and protein structures, and
often produces more of them than before the exercise. Skeletal muscle hypertrophy
occurs when the rate of muscle protein synthesis from amino acids exceeds that of protein
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degradation (Goh & Millay, 2017).
Many of the amino acids that are recruited to repairing the muscle are used to
build the muscle attachment complexes that anchor fibers to a specific subset of the ECM
called the basement membrane. These attachments are made through a variety of
different proteins (See Figure 2). All of these proteins are coded for and produced from
different genes, for example, dystrophin is coded by the DMD gene and is just one of the
many different proteins that help the muscle fibers attach to the basement membrane. All
of these proteins must function correctly in order for this connection to hold and the
muscle fiber to function properly. Many muscle diseases have been shown to have
weakened fiber-basement membrane adhesion, especially congenital muscle diseases.
There are two specific receptor complexes: one is integrin-mediated and the other is
mediated by the dystrophin-glycoprotein complex (DGC). Both of these receptor
complexes span from the actin cytoskeleton through the muscle cell membrane to the
ECM using different adhesion proteins. It is important that all of these “links” in the
chain are properly attached to each other so that the muscle fibers are able to anchor
properly.
Actin is the main component in the cytoskeleton of cells. It is a protein that folds
flat and has a deep medial cleft that binds ATP which helps attach multiple strands
together (Pollard, 2016). When these strands bind together, they form long, stiff chains.
These chains form part of the cytoskeleton and are what give the cell its structure.
Specifically, in the DGC, dystrophin proteins attach to the actin cytoskeleton. Dystrophin
proteins (see gray box in Figure 2) are coded for by the human gene DMD. This is one of
the largest known human genes, containing 79 exons and making up roughly 0.1% of the
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whole genome (Gao & McNally, 2015). The dystrophin proteins then are bound to
sarcoglycan proteins, which consist of four transmembrane glycoproteins and respond to
muscle contractions, transducing mechanical information into a cellular signal (Tarakci &
Berger, 2016). The next protein structure in the attachment complex is dystroglycan (see
purple transmembrane protein in Figure 2). There is one gene DAG1 that encodes 2
subunits (alpha-dystroglycan and beta-dystroglycan) that are formed after posttranslational cleavage of the protein product. Glycosylation of alpha-dystroglycan (see
light purple chains coming off alpha-dystroglycan in Figure 2) is important in the
connection between alpha-dystroglycan and laminin in the basement membrane (see
orange crosses in Figure 2). Laminin is one of the most widely expressed ECM proteins
(Yao, 2017). It plays critical roles in embryonic development, especially the binding of
the muscle attachment complex to collagen fibers, the final “link” in the chain. Collagen
is a triple-helix molecule that exists in many different isoforms in many places in the
body (Bella, 2016). In the muscle attachment complex, all of these protein structures
attach to one another, and finally to collagen (see gray wavy proteins in Figure 2), where
the fiber is secured. When even one of these proteins is not made properly due to a
mutation that alters its function, the whole complex can fail. When the complex fails, it
results in a muscle disease, such as muscular dystrophy. Many muscular dystrophies are
linked to a specific gene that codes for a specific protein, such as Duchenne muscular
dystrophy resulting from a mutation in the DMD gene, resulting in improper function of
the dystrophin protein.
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Figure 2: Cell Adhesion Complexes are Made Through Many Different Proteins, Adapted
from Goody et al., 2015. Skeletal muscle cell adhesion is done through a variety of
proteins. All of these proteins are coded for in different genes and a mutation in any one
of those genes can cause a form of muscular dystrophy.
2. Muscle Disease
Congenital muscle diseases can be caused by mutations in the DNA sequence
which leads to altered function of the proteins that attach muscle fibers to the basement
membrane. When this happens, the fibers are likely to break from their attachment. Since
the fibers are under a lot of tension, they snap back and die, similar to stretching a rubber
band and then having it break. Common symptoms of congenital muscle disease in
children are abnormal motor movements such as having trouble with walking. As the
disease progresses, muscle atrophy, weakening and shrinking of the muscle, is seen and
sometimes the patient loses the ability to walk or has trouble using their arms. However,
different muscle groups are affected in different genetic diseases. Some diseases affect
muscles around the eyes, while others may only affect the muscles in the legs. The most
common muscle diseases are Duchenne and Becker muscular dystrophy (DMD and
BMD, respectively), which affect approximately 1 in every 5,500 to 7,700 men (males
7

are more likely to be affected) age 5 to 24 (CDC.gov, 2019) However, any mutation in
the genes that code for these proteins can cause a different variation of a muscle disease.
In the case of this study, mutations in the GMPPB gene can cause the protein alphadystroglycan to be post-translationally processed incorrectly, resulting in compromised
muscle-basement membrane adhesion. Other genetic mutations that can cause congenital
muscle diseases occur in ITGA7 (integrin alpha 7), LAMA2 (laminin alpha 2), and COL6RD (collagen VI) genes. These gene products all function in adhesion complexes that link
the skeletal muscle fibers to the basement membrane and a problem in just one of them
can cause a number of disease symptoms.
Laminin alpha 2 proteins are coded for in the LAMA2 gene and mutations in this
gene cause a congenital muscular dystrophy called LAMA2 CMD or merosin-deficient
congenital muscular dystrophy (MDC1A) (Yurchenco, McKee, Reinhard, & Rüegg,
2018). This form of MD is characterized as early onset and is often very severe. The
COL6-RD gene codes for collagen VI, an important link in the chain of the muscle
attachment complex. Mutations in this gene give rise to Ullrich congenital muscular
dystrophy (UCMD), occurring in 0.13 out of 100,000 individuals, and Bethlem
myopathy, occurring in 0.77 out of 100,000 individuals (NIH, U.S. Library of Medicine,
2019) (Butterfield et al., 2017). Patients with either one if these congenital muscular
dystrophies present with muscle weakness and atrophy along with severe joint
contractures, joint laxity, and keratosis pilaris (Butterfield et al., 2017). Mutations in
DAG1 or enzymes that glycosylate alpha-dystroglycan cause a group of muscle diseases
called dystroglycanopathies. These can be separated into primary and secondary
dystroglycanopathies. Primary dystroglycanopathies are when there is a mutation in the
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DAG1 gene, altering the state of the dystroglycan core protein which affects adhesion
(Brancaccio, 2019.). So far, there are only 3 published reports of primary
dystroglycanopathy, two of them being siblings (Geis et al., 2013). This project focuses
on secondary dystroglycanopathies, which are much more common than primary
dystroglycanopathies. Secondary dystroglycanopathy involves mutations in any gene that
codes for any enzyme involved in the glycosylation of the alpha-dystroglycan core
protein. Included in these genes are POMT1, LARGE1, GMPPB, and others.
3. GMPPB and Muscular Dystrophy
The specific secondary dystroglycanopathy explored in this project results from a
mutation in the guanosine diphosphate mannose (GDP-mannose) pyrophosphorylase B
(GMPPB) gene. The result is a form of muscular dystrophy called GMPPB-associated
dystroglycanopathy. When alpha-dystroglycan is produced, a group of carbohydrate
chains (O-mannose) are added, which help the protein to be correctly trafficked and
anchored to the proper basement membrane (Serafini et al., 2018). When alphadystroglycan cannot be trafficked to the right area, or does not obtain these sugar chains,
the muscle fiber will not be attached properly.
GMPPB catalyzes the formation of O-mannose carbohydrate chains from GDPmannose through O-mannosylation for glycosylating proteins, including alphadystroglycan (Carss et al., 2013). These carbohydrate chains can be seen as finger-like
projections off of the alpha-dystroglycan molecule (see light purple projections off dark
purple protein in Figure 2). Mutations that alter the function of the GMPPB gene have
been shown to lead to hypoglycosylation of alpha-dystroglycan (Carss et al., 2013).
Those that are affected with this disease have variable phenotypes. The most mildly
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affected individuals typically have little to no deficiencies in muscle use, while those who
are severely affected have muscle wasting, intellectual disabilities, and a few have been
shown to have other disorders such as epilepsy (Jensen et al., 2015). Muscle atrophy is
the most common symptom of GMPPB-associated dystroglycanopathy. So far, no animal
model has been generated to study this disease other than zebrafish. Carss et al., 2013
used a morpholino-mediated knock down zebrafish model and the Henry lab was the first
to generate a genetic model for GMPPB-associated dystroglycanopathy in zebrafish.
4. Zebrafish as a Model of Study
Zebrafish (Danio Rerio) have been widely accepted as a useful model for
developmental biology and genetics experiments. Zebrafish development is rapid, as
embryos fully develop their major organ systems, including cardiovascular, nervous,
digestive, and muscle systems, in less than a week (Sarasamma et al., 2017). While they
develop, the skin is transparent which makes observation and imaging of organ system
development especially easy and efficient. There is also high fecundity in zebrafish;
females are able to produce about 50-350 offspring in a week (Steffen et al., 2007). To
reproduce, zebrafish fertilization is external, which lets the embryos be collected shortly
after fertilization occurs, providing researchers access to all stages of development. The
high fecundity and rapid development allow for multiple experimental trials be conducted
over a relatively short amount of time.
The cost of maintenance of zebrafish is relatively low as well. The embryos do
not need food until 4 days post fertilization, which is the conclusion of many experiments
as their organs have already developed. Different transgenic or mutant lines are also able
to be purchased for relatively low cost and kept for over 2 years. The small size of the
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adult zebrafish also allows for multiple fish to be kept in the same tank, reducing the need
for multiple tanks at large sizes, keeping maintenance costs low.
Zebrafish are also used as a model of study due to the molecular tools available
and their genetic amenability. Examination of specific gene function through the
development of transgenic lines, large scale mutagenesis screens, or antisense gene
knockdown is highly achievable with zebrafish (Sarasamma et al., 2017). It has been
shown by the UK Sanger institute that almost 70% of human genes have functional
homologs in zebrafish, including many of the genes that code for the proteins that attach
the muscle fiber to the basement membrane (Liu et al., 2017). Genetic and functional
conservation is important because that means that zebrafish display similar phenotypes
resulting from the same mutations in their genome as humans. In other words, a mutation
in a gene that encodes for a protein involved in muscle attachment in a zebrafish will
produce similar muscle attachment deficiencies as mutations in the homologous human
genes.
Two common methods of investigating gene function in the zebrafish model are
morpholino-mediated protein knock down and CRISPR/cas9 mutagenesis. Morpholino
(MO) antisense oligomers are synthetic oligonucleotides that interfere with mRNA
translation or processing, which results in protein knock down or a “pseudo” mutant
scenario. Advantages to MOs are that large numbers of “pseudo” mutants can be
generated for experiments and maternal and embryonic proteins are both knocked down.
Disadvantages include only temporary protein knock down, injection variability, and offtarget effects (Blum, De Robertis, Wallingford, & Niehrs, 2015). Alternatively, we can
now relatively easily alter DNA sequences through CRISPR/cas9 mutagenesis. This
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system allows genome editing of different species using specific RNA segments and the
Cas9 enzyme to cut the target DNA sequence and replace it with a customized DNA
sequence (J. Liu et al., 2017). Research labs and institutes are using this technique to
create mutant lines of zebrafish to model different genetic diseases, including the Henry
lab where they used CRISPR mutagenesis in an attempt to make genetic models for 16
dystroglycanopathies.
There have been valuable clinical outcomes from zebrafish research, including a
MO drug that was approved by the FDA for treatment of DMD in September 2016. The
drug is called eteplirsen and it employs the use of antisense oligonucleotides to interfere
with pre-mRNA splicing of DMD, which excludes the specific exon targeted (Lim,
Maruyama, & Yokota, 2017). While this interference with DMD splicing was shown only
to delay the disease progression slightly, it is a step in the right direction for the use of
MOs in human clinical trials. With more exploration and resources aimed at these drugs,
treatment of congenital diseases, such as DMD, could be developed with MO drugs.
Basic research with MOs and CRISPR mutagenesis in zebrafish and other model
organisms is really what made this drug possible. Being able to model human diseases in
animals not only gives us a closer look into how diseases work, but also how to treat
them.

5. Zebrafish Muscle Development
The development and physiology of skeletal muscle in zebrafish shares many
commonalities with higher vertebrates, including mammals such as mouse and dog
models (Goody, Carter, Kilroy, Maves, & Henry, 2017). However, there are differences
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in the skeletal muscle of zebrafish compared to higher vertebrates that can be viewed as
experimental advantages. In zebrafish, the different muscle fiber types, fast-twitch vs
slow-twitch, are spatially segregated. This allows for the observation of fiber-type
specific effects when experimenting while also providing an opportunity for identifying
the mechanisms that regulate fiber-type specification (Goody et al., 2017). Development
of the muscle is also easily observed. Skeletal muscle development in zebrafish is rapid
and completed in a few days. The muscle originates from somites with somitic cells as
the precursors to the individual fibers. These precursor cells elongate and eventually
become the actual muscle fibers, which are then separated into segments called
myotomes (See Figure 3) (Snow, Peterson, Khalil, & Henry, 2008). These myotomes are
characterized by having a sideways “V” shape, also known as a chevron, with an angle of
approximately 90º.

Figure 3: The Development of Skeletal Muscle from Somites: Adapted from Goody,
Carter, Kilroy, Maves, & Henry, 2017. The development of skeletal muscle starts with the
somite (pictured on the right) which contains short-precursor cells. These cells elongate,
attach to ECM, and then form the multinucleated striated skeletal muscle fibers within
the myotome (pictured to the left).

The lines that separate the individual myotomes are the myotendinous junctions
(MTJs). This is the site of attachment for the individual muscle fibers. The same proteins
involved with human muscle fiber attachment are also involved with fiber attachment in
zebrafish.
13

6. Zebrafish Models of Muscle Disease
Zebrafish have been used to model muscle disease, including muscular dystrophy
and dystroglycanopathy, across the world. They are one of the smallest models of muscle
disease used today. Dystrophin-deficient zebrafish, a model of DMD, are especially
useful for large-scale drug discovery screens, as they share characteristic morphological,
physical, and genetic features with mammals, but also have high fecundity and rapid
development (Widrick et al., 2016). For example, it was found that the chemical
aminophylline, was able to restore muscle structure in dystrophin deficient DMD
zebrafish mutants (Kawahara & Kunkel, 2013). Merosin-deficient congenital muscular
dystrophy (MDC1A), a laminin-associated muscular dystrophy, has also been modeled in
zebrafish. Laminin chains have major signaling functions in skeletal muscle, so altering
the structure of this molecule could have major consequences on muscle development
and structure (M. Li & Arner, 2015). Being able to model this in the zebrafish is
especially helpful in attempting to treat this form of muscular dystrophy. Studies in the
zebrafish MDC1A model showed that muscle fibers detach from the basement membrane
before cell death occurs, which is different than in the zebrafish DMD model where cell
death occurs before detachment (Hall et al., 2007). A severe form of muscular dystrophy,
Ullrich congenital muscular dystrophy (UCMD), has been modeled in zebrafish via MO
knock down of collagen VI. The model has let us obtain a better understanding on how
collagen VI is involved in this form of MD (Radev et al., 2015).
With new techniques in mutagenesis and as zebrafish rise in the ranks as models
of studying muscle disease, we are able to look at muscle development and disease under
an entirely different light. We have learned so much not only about the underlying causes
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of muscle disease, but we have connected the physiological consequences to the genetic
alterations that cause these diseases. It is a long path until we are able to treat these
diseases, but we come closer and closer every day.

7. The Thesis Project
In GMPPB-associated dystroglycanopathy, a mutation in the GMPPB gene will
cause hypoglycosylation of the alpha-dystroglycan protein. In our zebrafish GMPPBassociated dystroglycanopathy model generated with CRISPR/cas9 mutagenesis, we find
muscle disease is characterized by two distinct characteristics: broken muscle fibers
within the myotome and crossing of muscle fibers over the MTJ. From a transcriptomics
screen, we found an upregulation of matrix metalloproteinase 13 (mmp13) at the RNA
level in gmppb mutant zebrafish leading us to hypothesize that Mmp13 plays a role in
causing these two muscle phenotypes. MMPs are a group of enzymes that are involved
with the breakdown of the ECM and tissue remodeling (Pasiakos, Lieberman, &
McLellan, 2014). If a mutation in the gmppb gene is causing an upregulation of mmp13,
the protein could also be upregulated. Being an ECM and tissue remodeling enzyme, this
protein could be breaking down parts of the muscle attachment complex, or muscle ECM.
This project is a characterization of one of the CRISPR models of secondary
dystroglycanopathy, GMPPB-associated dystroglycanopathy. Specifically, we studied the
role of mmp13 upregulation in these gmppb mutated zebrafish. We used chemical
inhibition of Mmp13 in the mutants and morphants to see if we could prevent the two
main symptoms of the disease: broken muscle fibers and MTJ boundary crossings. We
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hypothesized that the inhibition of Mmp13 would lead to a “rescue” of these gmppb
phenotypes.
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MATERIALS AND METHODS

1. Zebrafish Strains, Care, and Maintenance
Adult zebrafish were kept at 28.5 ºC on a 16 h light/8 h dark cycle. Zebrafish
embryos were collected from natural spawning of these adult fish. Embryos were staged
according to Kimmel, Ballard, Kimmel, Ullmann, & Schilling, 1995. Experiments were
conducted with the approval of the University of Maine Institutional Animal Care and
Use Committee (IACUC). Embryo Rearing Media (ERM) was made in a 1 L bottle with
0.3 g NaHCO3, 50 mL 20x ERM stock, and brought to 1 L with ddH2O. Two drops of
methylene blue were added after the ddH2O. The wild-type lab strain of zebrafish used
was AB. The macrophage transgenic line was from by Pagán et al., 2015. The gmppb
mutant line was generated by the Henry Lab at the University of Maine.

2. CRISPR Mutagenesis
CRISPR/cas9 mutagenesis was performed as described in Gagnon et al., 2014.
Injected zebrafish (F0 generation) were grown to adulthood and identified as carriers of
gmppb mutations via PCR for the inserted stop codon cassette or through pair-wise
spawns that produced embryos with abnormal phenotypes. Experiments in this thesis
involved spawning F2 adult gmppb mutant carriers and analyzing the F3 generation of
embryos.
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3. Morpholino (MO) injections
MOs were purchased from Gene Tools, LLC and injected as in Carss et al., 2013,
except that p53 MO was not used. 3 ng of MOs was injected into each embryo at the 1-4
cell stage. MOs were injected with a MPPI-2 Pressure Injector from ASI.

4. In situ Hybridization
In situ hybridization (ISH) was performed as described in Jowett, 1999. Briefly,
embryos were dechorionated and put in 4% paraformaldehyde (PFA) for 4 hours at room
temperature or overnight at 4 ºC. The embryos were then washed 5 times for 5 minutes
each with Phosphate Buffer Saline (PBS) with 0.1% tween-20. The embryos were
incubated in prehybridization solution (50% Formamide, 5x sodium chloride-sodium
citrate buffer, 50 µg/mL Heparin, 500 µg/mL Yeast tRNA, 0.1% tween20, pH of 6.0 with
citric acid) for 4 hours at 65 ºC, and then hybridized at 65 ºC overnight with a
digoxygenin-labeled probe. Embryos were washed using serial dilutions into and out of
2x saline-sodium citrate (SSC), then incubated in anti-digoxygenin Ab (Roche) for 2
hours at room temperature, washed, and then developed in 0.45% NBT/0.35% BCIP
(Roche) until the embryos reached the desired color. The developing process was stopped
by fixing with 4% PFA or rinsing 4 times in sterile water. The probe was designed to
hybridize to zebrafish mmp13a and had a forward primer sequence of: 5’-TGG TGA
GAA ACG TTC CAG CGA TGT-3’ and a reverse primer sequence of (including the t7
bacterial promoter sequence): 5’-GTA ATA CGA CTC ACT ATA GGG CAC TCT TGG
GAT AGC CTT GCA CCA T-3’.
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5. MMP13 Inhibitor Experimental Setup
MMP13 inhibitor (CL82198 – 10 mg) was purchased from TOCRIS. It was
dissolved in DMSO to 10mM, aliquoted, and stored at –20 ºC. Zebrafish were exposed to
10 uM MMP13 inhibitor diluted in 1X ERM. All treatments were set up with 5 mL ERM
in 25 mL petri dishes with the addition of 5 µL solution if applicable (dose taken from
(Lisse et al., 2016). The embryos were dechorionated at 1 dpf and separated based on
whether they were wild type, had a subtle phenotype, or a severe phenotype, then placed
in the proper treatment. There were three setups for the treatments: 1) The controls,
having 5 mL ERM, 2) The MMP13 inhibitor group having 5 mL of ERM with 5 µL of
the MMP13 inhibitor stock solution, and 3) DMSO control group having 5 mL ERM with
5 µL of DMSO added. Each solution was discarded and replaced approximately every 24
hours until 4 days post fertilization (dpf). Any dead embryos (determined by having no
heartbeat) were removed if necessary every time the solution was changed. At the end of
4 dpf, the fish were removed from the treatments, fixed, and stored to be prepared for
staining.

6. Fixation
The embryos were placed in 4% paraformaldehyde for 4 hours at room temp or
overnight at 4 ºC. They were then washed out 3 times rapidly with PBS 0.1% Tween. The
embryos were then stored in PBS 0.1% Tween at 4 ºC until it was time to perform
immunohistochemistry.
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7. Immunohistochemistry
After the embryos were fixed, they were washed with decreasing volumes of PBS
0.1% Tween rapidly 3 times. The embryos were then put in 2% triton PBS and rocked for
1.5 hours at room temperature. They were then rinsed 2x quickly with PBS 0.1% Tween
and 20 µL of a 1:20 ratio of phalloidin 546 to PBS 0.1% Tween was added to each tube
and the tubes were kept under foil at 4 ºC overnight. The embryos were rinsed with PBStween and rocked 5 rounds for 5 minutes. Antibody (AB) block was added to the tubes
for one hour and then replaced with a 1 µL primary antibody to 200 µL AB block dilution
and kept at 4 ºC overnight. Primary antibody was removed and replaced with AB block
for approximately 8 hours at room temperature. The polyclonal secondary antibody was
then put in at a 1 µL to 200 µL ratio to AB block and kept at 4 ºC overnight. Then the
antibody was pipetted out and 0.1% tween was added. The embryos were then stored in 4
ºC until ready to be deyolked and mounted. The MMP13 hinge primary antibody was
purchased from Anaspec and secondary, fluorophore-conjugated antibodies were
purchased from Molecular Probes.
8. Deyolking and Mounting
The yolk of the embryos was removed in PBS using insect pins superglued into
glass capillary tubes and 2-5 embryos were mounted on a microscope slide in 80%
glycerol/20% PBS and covered with a cover slip held up by vacuum grease feet.

9. Imaging
After fixation, immunohistochemistry, deyolking, and mounting, the embryos
were imaged on a Leica confocal DMi8 with a 10x/0.40 HC PL APO objective.
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Maximum projections of z-stacks were generated and then the images were analyzed.
Images were pseudo-colored and merged in Adobe Photoshop.

10. Data Analysis
After images of the fish were taken, they were analyzed for two types of data. 1)
The number of broken fibers and MTJ boundary crossings were counted. The percent of
myotome segments with a broken fiber per embryo and boundary crossings per embryo,
along with the average of those percentages were then calculated. The percentages of
each were then graphed. 2) The images were checked for co-localization of Mmp13
protein and fluorescent macrophages.

11. Statistical Analyses
The averages and standard error of the mean of the data collected were calculated
and graphed using GraphPad Prism 7. T-tests and ANOVA of the above data were also
calculated for statistical significance through GraphPad Prism 7.
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RESULTS

1. In situ Hybridization Confirms mmp13a Upregulation
Preliminary RNA-sequence data showed that zebrafish isoforms of mmp13 were
upregulated in 4-day old gmppb mutants compared to wild-type siblings. To determine
the spatial location of mmp13 upregulation in the gmppb mutants, we performed in situ
hybridization (ISH) in 4-day old gmppb mutants and wild-type siblings. An antisense
probe was made to compliment a 500 bp region of zebrafish mmp13a. In 2 experiments,
we saw upregulation of mmp13a in the ventral, medial region of myotomes in cells with a
morphology and location suggesting they could be white blood cells. These data confirm
the RNA-sequence data and suggest that mmp13a upregulation in gmppb mutants is due
expression in some type of white blood cell localized in the ventral, medial region of the
body (See purple dots in Figure 4).
Because we saw upregulation of mmp13a in mutants relative to wild-types at 4
dpf, we performed ISH for mmp13a at earlier timepoints to determine when the mutants
first begin to express more mmp13a than wild-types. We performed mmp13a ISH on 2, 3
and 4-day old gmppb mutants and wild-type siblings. At 2 dpf, both wild-types and
gmppb mutants showed mmp13a expression in what we believed to be white blood cells
in the ventral, medial trunk (Figure 5 top panels). At 3 dpf, mmp13a expression was
absent in the trunk of wild-types yet remained expressed in gmppb mutants (Figure 5
bottom panels). Therefore, mmp13a was found to be upregulated at 3 dpf in gmppb
mutants compared to wild-types. A similar upregulation of mmp13a was again seen in 4day old gmppb mutants compared to wild-types. Normally, Mmp13a is silenced starting
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around 3 dpf, however this is not the case for gmppb mutants. These results suggest that
mmp13a expression is upregulated beginning at 3 dpf in presumptive white blood cells in
gmppb mutants compared to wild type siblings.

WT

gmppb

Figure SEQ Figure \* ARABIC 4: in situ hybridization results of
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2. Chemical Inhibition of Mmp13 Does not Rescue gmppb Mutants
Next, we sought to determine the functional consequence of mmp13 upregulation
on the muscle phenotype of gmppb mutants using a chemical inhibitor of Mmp13 protein
at a dose previously shown to have an effect in zebrafish (Lisse et al., 2016). Gmppb
mutants have been shown to have two main muscle phenotypes along with upregulated
mmp13: fiber breakage and/or MTJ boundary failure. To see if we could reduce the levels
of fiber breakage and MTJ crossovers, we used a chemical inhibitor to block the activity
of the Mmp13 protein. The images taken and analyzed from the confocal microscope
showed that there were similar levels of both broken fibers (see embryo pictures in Figure
6 and image quantification in Figure 7) and boundary crossings in gmppb mutants (see
embryo pictures in Figure 8 and image quantification in Figure 9) that were untreated,
DMSO treated, or Mmp13 inhibitor treated. These data do not support the hypothesis that
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chemical inhibition of Mmp13 reduces the amount of fibers that break or cross
boundaries in gmppb mutants.

Figure 6: Fiber breakage is not reduced in gmppb mutants through chemical inhibition
of mmp13. Fiber breakages in gmppb mutants for the untreated controls (A), DMSO
controls(B), and MMP13 inhibitor group (C) are characterized by a brighter spot in the
myotome. Broken fibers are indicated by a red arrow. From this data, we can conclude
that inhibition of MMP13 does not reduce fiber breakage in gmppb mutants.

Figure SEQ Figure \* ARABIC 6: Fiber breakage is not reduced in gmppb mutants through
chemical inhibition of mmp13. Fiber breakages in gmppb mutants for the untreated controls
(A), DMSO controls(B), and MMP13 inhibitor group (C) are characterized by a brighter spot
in the myotome. Broken fibers are indicated by a red arrow. From this data, we can conclude
that inhibition of MMP13 does not reduce fiber breakage in gmppb mutants.
Figure 7: Graph showing the percent of myotomes per embryo with a broken fiber in
gmppb mutants with the mean and standard error of the mean. The average percent of
the untreated controls, DMSO controls, and Mmp13 inhibitor group were 13.07, 10.48,
and 11.43, respectively. The results from an ANOVA test for untreated vs DMSO was
0.77, untreated vs Mmp13 inhibitor was 0.97 and for DMSO vs Mmp13 inhibitor was
0.94. These p-values do not imply statistical significance. These results do not support
our hypothesis that chemical inhibition of Mmp13 would reduce the fiber breakage in
gmppb mutants.
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Figure 8: MTJ boundary crossings boundary crossings are not reduced in gmppb
mutants. MTJ boundary crossings in the untreated controls (A), the DMSO controls (B),
and the MMP13 inhibitor group (C) are indicated by the red arrows. From this data, the
inhibition of MMP13 did not lead to a decrease in boundary crossings in gmppb mutants.

Figure 9: Graph showing the percent of myotomes with an MTJ failure in gmppb mutants
with the mean and standard error of the mean. The average percent of the untreated
controls, DMSO controls, and Mmp13 inhibitor group were 17.89, 15.76, and 13.42,
respectively. The p-values from an ANOVA test for untreated controls vs DMSO controls,
untreated controls vs the inhibitor group, and the DMSO controls vs the inhibitor group
were all 0.99 which does not imply statistical significance. These results do not support
our hypothesis that chemical inhibition of Mmp13 would reduce MTJ failure in gmppb
mutants.
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3. Mmp13a is Upregulated at 4 dpf in gmppb Morphants Compared to Controls
The results of the figures and the images taken from the microscope showed us
that chemical inhibition of Mmp13 did not slow the progression of the
dystroglycanopathy in gmppb mutants. However, the spawns of gmppb mutants were
variable, as some had worse phenotypes than others and some seemed like they had no
phenotypes at all. Because of this, we sought to use MOs to knock down Gmppb. First,
we confirmed through ISH that mmp13a is upregulated in gmppb morphants at 4 dpf and
saw a similar upregulation and expression pattern for mmp13a in gmppb morphants
compared to un-injected controls as we did in the gmppb mutants (data not shown).

4. Chemical Inhibition of Mmp13 Does Not Rescue gmppb Morphants
Now that upregulation of mmp13a at the RNA level is confirmed in gmppb
morphants, we sought to use chemical inhibition of Mmp13 with these morphants to see
if we could slow the progression of the muscle disease through the reduction of fiber
breakages and MTJ failures. We repeated the previous experiments we did with the
mutants with the morphants and analyzed for the same results. Gmppb morphants treated
with Mmp13 inhibitor did not display fewer broken fibers than untreated gmppb
morphant controls or DMSO treated gmppb morphant controls (see Figure 10 for image
quantification data).
When analyzing the images, the morphant myotomes were mostly too poorly
organized to properly see if the muscle fibers crossed the MTJ. We did not want to make
any false inferences when extracting this data, so we did not analyze the images for MTJ
crossings.
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Figure 10: Graph showing the percent of myotomes per embryo with a broken fiber in
gmppb morphants with the mean and standard error of the mean. The average percent of
the untreated controls, DMSO controls, and Mmp13 inhibitor group were 16.11, 11.32,
and 20.79, respectively. The results from an ANOVA for the untreated controls vs the
DMSO controls was 0.71, the untreated controls vs the inhibitor group was 0.78, and the
DMSO controls vs the inhibitor group was 0.43. These results do not imply statistical
significance. These results do not support our hypothesis that chemical inhibition of
Mmp13 would reduce fiber breakage in gmppb morphants.

5. Mmp13 Protein Does Not Appear Upregulated in gmppb Morphants
One possible explanation for the chemical inhibitor not having an effect on either
the gmppb mutants or morphants would be that there was no upregulation of Mmp13 at
the protein level. ISH only showed us that mmp13a is upregulated at the RNA level. Our
chemical inhibitor would only be effective at preventing the activity of Mmp13 protein.
To determine if Mmp13 was upregulated at the protein level, we used
immunohistochemistry to antibody stain for Mmp13 protein level expression using an
anti-MMP13 hinge antibody from Anaspec. One small preliminary experiment showed
that there was Mmp13 staining in cells that, based on location and morphology, appear to
be red and white blood cells. This staining pattern was seen in both controls and gmppb
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morphants and did not appear upregulated in gmppb morphants relative to controls (see
Figure 11).

6. Mmp13 Protein Does Not Co-localize with Macrophages
We also used immunohistochemistry to see if there was co-localization of Mmp13
with macrophages. We used Tg(mpeg1:GFP) fluorescent transgenic zebrafish (Pagán et
al., 2015) injected with gmppb MOs to observe whether Mmp13 protein and fluorescent
macrophages co-localize. In one small preliminary experiment, we found that there was
not exact co-localization of Mmp13 and macrophages in either the morphants or the
controls (See Figures 11 and 12). Mmp13 protein seemed to be located adjacent to the
macrophages. Macrophages could be producing the Mmp13 and then secreting the
protein out into the ECM. However, if there was secretion from macrophages, we would
still expect to see some Mmp13 protein co-localize with macrophages.

Figure SEQ Figure \* ARABIC 11: Staining for mmp13 and macrophages does not show colocalization in the wt control trunk or tail. The stain for macrophages (left) and mmp13 antibody
(middle) was merged (right) to see if there was any co-localization of mmp13 and macrophages.
From the images taken, we did not see co-localization of mmp13 and macrophages in the wt
Figure 12: Staining for mmp13 and macrophages does not show co-localization in gmppb morphant
controls.
trunk or tail. The stain for macrophages (left) and mmp13 (middle) was merged (right) to see if there
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would be any co-localization of mmp13 and macrophages.
From the images taken, we did not see colocalization of mmp13 and macrophages in gmppb morphants.

Figure 11: Staining for mmp13 and macrophages does not show co-localization in the wt
control trunk or tail. The stain for macrophages (left) and mmp13 antibody (middle) was
merged (right) to see if there was any co-localization of mmp13 and macrophages. From
the images taken, we did not see co-localization of mmp13 and macrophages in the wt
controls.
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Figure 12: Staining for mmp13 and macrophages does not show co-localization in
gmppb morphant trunk or tail. The stain for macrophages (left) and mmp13 (middle) was
merged (right) to see if there would be any co-localization of mmp13 and macrophages.
From the images taken, we did not see co-localization of mmp13 and macrophages in
gmppb morphants.
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DISCUSSION

The results of RNA-seq and ISH showed us that there is an upregulation of
mmp13a in the gmppb mutants and morphants at the RNA level. This upregulation, we
believed, could be a contributor to the progression of GMPPB-associated
dystroglycanopathy, and inhibition of Mmp13 would be able to rescue the mutants and
morphants. However, from the results of the experiment, we can see that chemical
inhibition of Mmp13 does not rescue the phenotype of either the gmppb mutants or
morphants like we had previously believed it would.
Throughout the course of these experiments, we encountered issues with our
animal models. The variability in phenotypes of the gmppb mutants was a large issue
with the first part of the experiment. We were unable to take the genotype of each
individual embryo in each treatment due to lack of time and resources, so we relied on
phenotypic sorting. Without the genotype, we were not able to confirm whether or not the
embryo had the specific mutation in the gmppb gene. Using MO injections was the next
option, as we had already confirmed the upregulation of mmp13a at the RNA level in
gmppb morphants. However, the phenotypes of the morphant were much more severe
than that of the mutants. This could be due to the fact that MO knockdown of gmppb
blocks both maternal gene products and embryonic gene products, while the mutant
embryos only had their embryonic gene products altered. When an embryo is developing,
maternal RNA produces many of the gene products that are crucial for this development.
Once the maternal RNA runs out, then embryo starts producing its own gene products. A
mutation in the embryo will not show a phenotype until the embryo’s maternal RNA
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degrades and the embryonic RNA starts being used. When using MO knockdown, both
the RNA from the mother and the embryonic RNA is blocked. This, in consequence,
could lead to a worse phenotype in the morphant (if gmppb is maternally expressed), as
the gmppb gene is blocked right at the start of development. Another possibility for the
discrepancy between morphant and mutant phenotypes is that the gmppb mutation (which
we think is a hypomorphic scenario) could result in more functional Gmppb protein than
in the morphant. Overall, being able to combat the variability in the gmppb mutants or
reducing the severity of the gmppb morphant phenotype would be key in improving this
experiment and solidifying our results.
While we were clearly able to observe the consequences of the mutated gmppb
gene and the MO knockdown, the chemical inhibitor was not able to rescue the embryos
affected with the disease. There are a couple of possibilities for the inhibitor not working.
One of the reasons is that the chemical inhibitor only inhibits Mmp13 activity at the
protein level, and we were only able to confirm upregulation of mmp13 at the RNA level.
There is a possibility that the protein was not translated from the mmp13 RNA.
Differences in protein vs mRNA levels have been seen before. Liu et al., 2016 showed
that there is a heavy influence in the relationship between protein levels and their coding
transcripts as a result of the temporal and spatial variations of mRNAs, as well as the
local availability of resources for protein biosynthesis. While it is possible that there are
varying levels of RNA vs protein, I couldn’t find an example of the protein not being
produced while the RNA is upregulated in the current literature. This makes it more
likely that using Mmp13 inhibition as a way to treat GMPPB-associated
dystroglycanopathy may not be a worthwhile method.
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There is also the possibility, if Mmp13 protein was in fact upregulated, that we
added the chemical inhibitor at the incorrect time and/or dose to be able to inhibit the
Mmp13 protein. We determined the dose and time of administration from Lisse et al.,
2016, as their study found that this dose and time produced significantly different results
in axon regeneration in zebrafish. To see if this dose worked in our study, we would have
to conduct an experiment that tested different doses at different stages of development.
We did not perform this trial before our experiment because we did not have the time or
the resources to perform this and the actual experiments in the academic year.
Another factor that would preclude the chemical inhibitor from rescuing the
GMPPB-associated dystroglycanopathy muscle phenotype is that there may have been
earlier developmental processes that were disrupted before we added the chemical
inhibitor. If even just one process did not take place normally, this could cause a whole
cascade of consequences. If this was the case, there would not be anything we could do to
control it unless we could identify the developmental process that was affected in the first
few hours of development. However, we don’t believe this to be the case because
mmp13a was normally expressed in both wild type and gmppb mutants at 2 dpf and the
only difference in gene expression was detected at 3 and 4 dpf. We added the Mmp13
inhibitor at 1 dpf, which was a developmental stage prior to when mmp13 expression
became different.
When analyzing the images for co-localization of Mmp13 and macrophages, we
found that there was none. While the Mmp13 staining had a morphology consistent with
macrophages, the Mmp13 was adjacent to but not overlapping with any transgenic
fluorescent macrophages. One hypothesis for this is that the Mmp13 protein could have
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been secreted by a nearby cell. This is unlikely, however, as the antibody we used stains
the hinge region of the Mmp13 protein, which is present in both the proenzyme and the
mature enzyme. If it was the macrophages that were secreting Mmp13, we would be able
to see the proenzyme stained within the macrophages. There could be other cells in the
area that could be secreting Mmp13, so we would need to stain for other cell types and
see which ones co-localize with Mmp13 protein. One possibility could be that neutrophils
are secreting Mmp13. Neutrophils are another type of white blood cell that resides with
macrophages in the zebrafish embryo during this stage. We would need to use antibody
staining or a fluorescent transgenic line to visualize neutrophils and stain for Mmp13
protein as well. If we see co-localization of Mmp13 and neutrophils, we would be able to
confidently suggest that these are the cells secreting the Mmp13 protein. Mmp13 has
been shown to be secreted by neutrophils as well as macrophages (Lin, et al., 2015).
Dendritic cells and mast cells have also been shown to produce Mmp13 under certain
circumstances (X.-D. Li et al., 2017), (Lin, Yeh, Li, & Chang, 2015).
There are many aspects of this experiment that could be modified if we decide to
explore this topic further. First, taking the genotype of the gmppb mutants would allow us
to be able to confidently identify which embryos have received the mutation and we
would not have to rely on observing the phenotype of the embryo. This rules out the
possibility that the fish may have had a developmental issue that looked as though they
were affected by the disease, which could also help alleviate the variability we observed
in the mutants. Being able to take out the embryos that are not affected by the disease
would save time and money, as we wouldn’t be treating any embryos that were not
gmppb mutants.
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Instead of using a chemical inhibitor to block the activity of Mmp13, it would be
advantageous to be able to genetically inhibit mmp13. We could use CRISPR/Cas9 to
create a mutant line of mmp13 mutant zebrafish. However, zebrafish have 2 isoforms of
mmp13 and we would have to cross these mutant lines to the gmppb mutant line. This
would require a triple mutant line, which would take a long time to raise to sexual
maturity for spawning and the odds of getting triple mutant embryos would be 1:64.
Another way the experiment could be improved upon would be to test for colocalization of Mmp13 and neutrophils or other white blood cell types. To view the
neutrophils, we could use a transgenic line of zebrafish that shows fluorescent
neutrophils. Staining for Mmp13 would show us whether there was co-localization of
Mmp13 and neutrophils, which would help us answer the question of where the Mmp13
is coming from. If there is no co-localization, we would have to continue to find a cell
type that co-localizes with Mmp13 protein.
To improve the experiment, we could also run trials to determine whether or not
the dose of the inhibitor and the time it was administered were effective. We tried to
model the inhibitor administration after a human clinical trial, as a patient wouldn’t be
given a drug until the doctor is able to see the phenotype and obtain the genotype to
confirm the presence of GMPPB-associated dystroglycanopathy.
While ISH showed us that mmp13a is upregulated in gmppb mutant zebrafish, we
were not able to rescue either the gmppb mutants or the morphants through chemical
inhibition of Mmp13. This shows that this chemical inhibition of the protein may not be a
viable way of treating this disease. However, improvement of our experiment and further
exploration of possible treatments for GMPPB-associated dystroglycanopathy would
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enhance our understanding of the disease, the underlying mechanisms, and the symptoms
to hopefully move towards better treatment options in the future.
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